共 250 条
[1]
Kasuno K(2003)Hepatitis C virus-associated tubulointerstitial injury Am J Kidney Dis 41 767-775
[2]
Ono T(2004)Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: the DOPPS Kidney Int 65 2335-2342
[3]
Matsumori A(2012)Impact of hepatitis C on survival in dialysis patients: a link with cardiovascular mortality? J Viral Hepat 19 601-607
[4]
Nogaki F(2007)The impact of hepatitis C virus infection on survival in dialysis patients: meta-analysis of observational studies J Viral Hepat 14 697-703
[5]
Kusano H(2014)Hepatitis C virus infection increases risk of developing end-stage renal disease using competing risk analysis PLoS One 9 e100790-1898
[6]
Watanabe H(2014)Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection N Engl J Med 370 1889-2607
[7]
Yodoi J(2015)Sofosbuvir and Velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection N Engl J Med 373 2599-1887
[8]
Muso E(2013)Sofosbuvir for previously untreated chronic hepatitis C infection N Engl J Med 368 1878-751
[9]
Fissell RB(2017)KDOQI US commentary on the 2017 KDIGO clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD) Am J Kidney Dis 70 737-511
[10]
Bragg-Gresham JL(2018)Electronic address eee, European Association for the Study of the L. EASL recommendations on treatment of hepatitis C 2018 J Hepatol 69 461-3633